DOCSLIB.ORG

Potential Benefits of Ketamine Seen in Antidepressent Clinical Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Potential Benefits of Ketamine Seen in Antidepressent Clinical Trial Clin. Invest. (2013) 3(7), 609–612 NEWS Highlights from the latest news and research in Clinical Investigation Potential benefits of ketamine seen in antidepressent clinical trial The largest clinical trial to date utiliz- TX, USA) and James Murrough (Mount placebo-administered group. For both ing the anesthetic ketamine was led by Sinai, NY, USA) along with their research groups the drugs were well tolerated. researchers from the Icahn School of team. Seventy two patients with treat- Murrough summarized the study Medicine (Mount Sinai, NY, USA). ment-resistant depression (classified as findings, “We found that ketamine was The clinical trial enrolled patients diag- failure to respond to two or more med- safe and well tolerated and that patients nosed with treatment-resistant major ications) were evaluated and underwent who demonstrated a rapid antidepressant depression who were treated with ket- either a single intravenous infusion of effect after starting ketamine were able amine – and within 24 h the antide- ketamine over the course of 40 minutes to maintain the response throughout the pressant benefits of the anesthetic were or were treated with the active placebo course of the study.” He also added that reported. Traditional antidepressants midazolam. Midazolam is also an anes- for future studies, “Larger placebo-con- can normally take between several days thetic but does not possess antidepressant trolled studies will be required to more to weeks to demonstrate an improvement properties. Patients were interviewed after fully determine the safety and efficacy in depression. 24 h, and then again after 7 days had profile of ketamine in depression.” passed. The response rate was 63.8% after – Written by Priti Nagda “…within 24 h the antidepressant 24 h for patients in the ketamine-treated benefits of the anesthetic were group in comparison with 28% in the Sources: Mount Sinai Hospital, Newsroom, reported.” active-placebo group. Seven days later the news releases: www.mountsinai.org/about-us/ response to ketamine was lasting, with a newsroom/press-releases/ The mechanism of action of tradi- 47.5% response for the ketamine-treated ketamine-shows-significant-benefit-in- tional antidepressants such as selective group in comparison with 18.2% for the people-with-treatment-resistant-depression serotonin reuptake inhibitors is to con- trol the neurotransmitter activity of norepinephrine and serotonin to cause a reduction in depression. However, with these medications the response can be largely delayed, and according to statis- tics from the US Department of Health, up to 60% of patients do not respond to this type of treatment. Ketamine on the other hand controls the activity of the glutamine neurotransmitter, and appears to do so much quicker than the traditional antidepressants. “…according to statistics from the US Department of Heath, up to 60% of patients do not respond to [traditional antidepressants].” The study was led by Dan Iosifescu (Mount Sinai, NY, USA), Sanjay Mathew (Baylor College of Medicine, ISSN 2041-6792 10.4155/CLI.13.60 © 2013 Future Science Ltd 609 NEWS Data reported for gefitinib use in Caucasian EGF receptor mutation-positive non-small-cell lung cancer patients Novel data from the IFUM trial, pre- on investigators assessment in patients overall survival were reported to be 91%, sented at the European Multidisciplin- treated with gefitinib using Response 9.7 months and 19 months, respectively. ary Conference in Thoracic Oncology Evaluation Criteria in Solid Tumours ver- Douillard also explained, “The safety and (EMCTO; Lugano, Switzerland), have sion 1.1. Overall response rate was 70% tolerance profile in Caucasian patients demonstrated that IRESSA™ (gefitinib; (95% CI: 61–78%).” did not show any new signal. Remark- AstraZeneca, UK) is effective for Cauca- Data from the previous IPASS study ably, the incidence of grade 3/4 adverse sian patients with EGF receptor (EGFR) demonstrated superior PFS for gefitinib events was low with 0% grade 3 rash and mutation-positive advanced non-small- compared with intravenous carboplatin/ 3.7% diarrhea.” Overall survival data will cell lung cancer (NSCLC) in the first-line paclitaxel chemotherapy in a population require longer follow up. setting, based on objective response rate of patients with advanced NSCLC in As this evidence supports the use of and progression-free survival (PFS). Asia. Explaining the significance of the gefitinib in Caucasian patients, Douillard IFUM is a Phase IV open-label, multi- novel IFUM results, Douillard noted, hopes the results will increase physician center, single-arm study aiming to charac- “The objective response rate seen in confidence in prescribing gefitinib for terize the efficacy, safety and tolerability this EGFR mutation-positive Caucasian such patients. of gefitinib in 106 EGFR mutation-pos- population is similar to that seen in the – Written by Francesca Lake itive Caucasian NSCLC patients. Jean- EGFR mutation-positive IPASS popula- Yves Douillard, principal investigator of tion. Therefore, gefitinib appears to be Source: Press release: New data presented at the study (University of Nantes Medical consistent in its efficacy in patients with EMCTO showed that first-line therapy with School, France), explained, “The primary this disease, irrespective of whether they gefitinib (IRESSATM) in Caucasian patients end point of IFUM was to evaluate the are Asian or Caucasian.” with EGFR mutation-positive advanced NSCLC objective response rate (confirmed com- The secondary efficacy end points of resulted in an ORR of 70% (95% CI 61-78). plete response or partial response) based disease control rate, median PFS and Released 10th May 2013. The potential of Kava to be used as an alternative therapy for anxiety sufferers A world first study led by a research chronic clinical anxiety. Unlike some Patients in the placebo group were given team from the University of Melbourne other options it has less risk of depend- dummy tablets in the same fashion. By (Melbourne, Victoria, Australia) have ency and less potential for side effects.” the end of the study, results indicated found that Kava, a plant originating The study revealed that polymor- that there had been a significant reduc- from the South Pacific, may cause a phisms in GABA transporters may mod- tion in anxiety in the patients that had significant reduction in people who suf- ify a sufferer’s response to Kava, with been taking Kava in comparison to those fer from anxiety. Kava could become a Sarris explaining that, “If this finding is in the placebo group. potential alternative therapy for the many replicated, it may pave the way for simple The effects of Kava were apparently thousands of Australians suffering from genetic tests to determine which people greater in reducing anxiety in those generalized anxiety disorders (GADs). may be likely to have a beneficial anxiety- enrollments whose GAD had been diag- GAD is a complex condition that can reducing effect from taking Kava.” nosed as moderate-to-severe. After com- drastically affect a sufferer’s quality of The 8-week study consisted of 75 pletion of the controlled phase, 6% of life with existing therapeutics possessing patients who were clinically diagnosed participants in the placebo group were only a modest clinical effect. with GAD, being administered either shown to be in remission in comparison Jerome Sarris (University of Melbourne, Kava or placebo with their anxiety lev- to the 26% of the patients in the Kava Victoria, Australia) explained the need els assessed regularly. Those in the Kava group. for newer and more effective medica- group were administered tablets contain- Kava was seen to be well tolerated tions for those suffering from anxiety, ing a water-soluble extract of Kava; the with no significant differences in patient “Based on previous work we have rec- peeled rootstock twice daily for a com- liver-function tests across either group. In ognized that plant based medicines may bined dose of 120 mg of kavalactones addition, no adverse effects were found be a viable treatment for patients with during the primary 3-week controlled that could be solely attributed to Kava chronic anxiety. In this study we’ve been phase. In the event of nonresponse, par- and there were also no differences seen able to show that Kava offers a potential ticipants were increased to a double dose in the Kava and placebo groups regarding natural alternative for the treatment of twice daily for the second 3-week phase. addiction and withdrawal. 610 www.future-science.com future science group NEWS Further studies will now concentrate on – Written by Priti Nagda Kava in the treatment of generalized anxiety confirming the relationship between genet- disorder: a double-blind, randomized, ics and therapeutic response. The findings Sources: University of Melbourne, Melbourne placebo-controlled study. J. Clin. will be of potential benefit to both anxiety Alumni eNews: http://alumni.news.unimelb. Psychopharmacol. doi: 10.1097/ sufferers and the region of the South Pacific edu.au/clinical-trial-supports-use-kava-treat- JCP.0b013e318291be67 (2013) (Epub ahead of that relies on Kava as an export. anxiety; Sarris J, Stough C, Bousman CA et al. print). Uncertainty over the benefits of diabetes drug in breast cancer patients Metformin, a popular drug for diabetes as slowing tumor growth in breast cancer There are limitations to this study, as treatment, might not affect survival in breast patients. data on the stage of breast cancer and cancer patients, according to new results. The study involved 2361 diabetic women BMI were not included, and there were A new population-based study, pub- over the age of 66, all diagnosed with breast relatively short follow-up times (median lished in Diabetes Care has not shown a dif- cancer. The authors analyzed the associa- follow-up time was 4.5 ± 3.0 years). How- ference in survival from metformin use as tions between duration of metformin use ever, in general these results suggest that might have been expected, a result contrary and mortality in the population, broken more research is needed to clarify the role to some evidence that suggests the drug down into all-cause mortality and breast of metformin in cancer.
Load more

Recommended publications
  • Kava (Piper Methysticum) and Its Methysticin Constituents Protect Brain Tissue Against Ischemic Damage in Rodents
    5 Refs: Arletti R et al, Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual-behavior of male rats. Psychopharmacology 143(1), 15-19, 1999. Berger F, Handbuch der drogenkunde . Vol 2, Maudrich, Wien, 1950. Martinez M, Les plantas medicinales de Mexico . Cuarta Edicion Botas Mexico , p119, 1959. Tyler VE et al, Pharmacognosy , 9 th edition, Lea & Febiger, Philadelphia, 1988. KAVA ( Piper methysticum ) - A REVIEW The Kava plant (Piper methysticum) is a robust, well-branching and erect perennial shrub belonging to the pepper family (Piperaceae). The botanical origin remains unknown, although it is likely that early Polynesian explorers brought the plant with them from island to island. Numerous varieties of Kava exist, and today it is widely cultivated in several Pacific Island countries both for local use as well as the rapidly growing demand for pharmaceutical preparations. The dried rhizomes (roots) are normally used. The first description to the western world of the ceremonial use of an intoxicating beverage prepared from Kava was made by Captain James Cook following his Pacific voyage in 1768. The drink, prepared as an infusion in an elaborate manner after first chewing the root, is consumed on formal occasions or meetings of village elders and chiefs, as well as in reconciling with enemies and on a more social basis. It remains an important social custom in many Pacific Island countries today. Most of the islands of the Pacific possessed Kava prior to European contact, particularly those encompassed by Polynesia, Melanesia and Micronesia. After drinking the Kava beverage a pleasantly relaxed and sociable state develops, after which a deep and restful sleep occurs.
    [Show full text]
  • Alternative Treatments for Depression and Anxiety
    2019 PCB Conference: Strickland Benzodiazepines (BZDs), Herbal and Alternative Treatments for Anxiety & Depression BZD Learning Objectives • List at least three uses for benzodiazepines • Discuss at least two risk factors associated with benzodiazepine prescriptions Craig Strickland, PhD, Owner Biobehavioral Education and Consultation https://sites.google.com/site/bioedcon 1 2 BZD Pharmacokinetics Clinical Uses of BZDs Generic Name Trade Name Rapidity ½ Life Dose (mg) • Treat a variety of anxiety disorders alprazolam Xanax Intermediate Short 0.75-4 • Hypnotics • Muscle relaxants chlordiaze- Librium Intermediate Long 15-100 poxide • To produce anterograde amnesia clonazepam Klonopin Intermediate Long 0.5-4 • Alcohol & other CNS depressant withdrawal • Anti-convulsant therapy diazepam Valium Rapid Long 4-40 triazolam Halcion Intermediate Very short 0.125-0.5 temazepam Restoril Short Short 7.5-30 3 4 1 2019 PCB Conference: Strickland Issues with BZDs Herbal Medication and Alternative Therapies Used in the Treatment of Depression and Anxiety • Addictive potential • Confusion between “anti-anxiety” effects and the “warm-fuzzy) • Large dose ranges • Comparison of BZDs with medications like Buspar, etc. • They work, they work well and they work quickly 5 6 Alternative Tx. Learning Objectives Background Information on herbals: Natural does not necessarily mean “safe” • List several amino acid treatments for depression • Side-effects and adverse reactions • List at least three of the most common herbal – Herbal medications are “drugs” although
    [Show full text]
  • Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
    toxins Review Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 1 2 3, 4, , Marie-Line Reynaert , Denis Dupoiron , Edouard Yeramian y, Laurent Marsollier * y and 1, , Priscille Brodin * y 1 France Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France 2 Institut de Cancérologie de l’Ouest Paul Papin, 15 rue André Boquel-49055 Angers, France 3 Unité de Microbiologie Structurale, Institut Pasteur, CNRS, Univ. Paris, F-75015 Paris, France 4 Equipe ATIP AVENIR, CRCINA, INSERM, Univ. Nantes, Univ. Angers, 4 rue Larrey, F-49933 Angers, France * Correspondence: [email protected] (L.M.); [email protected] (P.B.) These three authors contribute equally to this work. y Received: 29 June 2019; Accepted: 3 September 2019; Published: 4 September 2019 Abstract: Pain currently represents the most common symptom for which medical attention is sought by patients. The available treatments have limited effectiveness and significant side-effects. In addition, most often, the duration of analgesia is short. Today, the handling of pain remains a major challenge. One promising alternative for the discovery of novel potent analgesics is to take inspiration from Mother Nature; in this context, the detailed investigation of the intriguing analgesia implemented in Buruli ulcer, an infectious disease caused by the bacterium Mycobacterium ulcerans and characterized by painless ulcerative lesions, seems particularly promising. More precisely, in this disease, the painless skin ulcers are caused by mycolactone, a polyketide lactone exotoxin. In fact, mycolactone exerts a wide range of effects on the host, besides being responsible for analgesia, as it has been shown notably to modulate the immune response or to provoke apoptosis.
    [Show full text]
  • Diazepam and Kava Combination Article
    Journal of Advanced Research (2014) 5, 587–594 Cairo University Journal of Advanced Research ORIGINAL ARTICLE Enhanced efficacy and reduced side effects of diazepam by kava combination Rasha A. Tawfiq a, Noha N. Nassar b,*, Wafaa I. El-Eraky c, Ezzeldein S. El-Denshary b a Egyptian Patent Office, Academy of Scientific Research and Technology, 101 Kasr El-Eini St., Cairo, Egypt b Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Eini St., Cairo, Egypt c Department of Pharmacology, National Research Center, El-Tahrir St., Giza, Egypt ARTICLE INFO ABSTRACT Article history: The long term use of antiepileptic drugs possesses many unwanted effects; thus, new safe com- Received 2 April 2013 binations are urgently mandated. Hence, the present study aimed to investigate the anticonvul- Received in revised form 18 July 2013 sant effect of kava alone or in combination with a synthetic anticonvulsant drug, diazepam Accepted 15 August 2013 (DZ). To this end, female Wistar rats were divided into two subsets, each comprising 6 groups Available online 22 August 2013 as follows: group (i) received 1% Tween 80 p.o. and served as control, while groups (ii) and (iii) received kava at two dose levels (100 and 200 mg/kg, p.o.). The remaining three groups received Keywords: (iv) DZ alone (10 mg/kg p.o.) or kava in combination with DZ (v) (5 mg/kg, p.o.) or (vi) (10 mg/ Kava kg, p.o.). Results of the present study revealed that kava increased the maximal electroshock Diazepam seizure threshold (MEST) and enhanced the anticonvulsant effect of diazepam following both Anticonvulsant acute and chronic treatment.
    [Show full text]
  • Kava Kava Extract Is Available from Ashland Chemical Co., Mini Star International, Inc., and QBI (Quality Botanical Ingredients, Inc.)
    SUMMARY OF DATA FOR CHEMICAL SELECTION Kava Kava 9000-38-8; 84696-40-2 November 1998 TABLE OF CONTENTS Basis for Nomination Chemical Identification Production Information Use Pattern Human Exposure Regulatory Status Evidence for Possible Carcinogenic Activity Human Data Animal Data Metabolism Other Biological Effects Structure-Activity Relationships References BASIS OF NOMINATION TO THE CSWG Kava kava is brought to the attention of the CSWG because it is a rapidly growing, highly used dietary supplement introduced into the mainstream U.S. market relatively recently. Through this use, millions of consumers using antianxiety preparations are potentially exposed to kava kava. A traditional beverage of various Pacific Basin countries, kava clearly has psychoactive properties. The effects of its long-term consumption have not been documented adequately; preliminary studies suggest possibly serious organ system effects. The potential carcinogenicity of kava and its principal constituents are unknown. INPUT FROM GOVERNMENT AGENCIES/INDUSTRY The U.S. Pharmacopeia is in the process of reviewing kava kava. No decision on preparation of a monograph has been made. SELECTION STATUS ACTION BY CSWG: 12/14/98 Studies requested: - Toxicological evaluation, to include studies of reproductive toxicity and neurotoxicity - Genotoxicity Priority: High Rationale/Remarks: - Significant human exposure - Leading dietary supplement with rapidly growing use - Concern that kava has been promoted as a substitute for ritilin in children - Test extract standardized to 30 percent kavalactones - NCI is conducting studies in Salmonella typhimurium CHEMICAL IDENTIFICATION CAS Registry Number: 9000-38-8 Kava-kava resin (8CI) Chemical Abstract Service Name: 84696-40-2 CAS Registry Number: Pepper (Piper), P. methysticum, ext. Chemical Abstract Service Name: Extract of kava; kava extract; Piper Synonyms and Trade Names: methisticum extract Description: The tropical shrub Piper methysticum is widely cultivated in the South Pacific.
    [Show full text]
  • Effects of Low-Dose and Very Low-Dose Ketamine Among Patients with Major Depression
    International Journal of Neuropsychopharmacology Advance Access published December 17, 2015 International Journal of Neuropsychopharmacology, 2015, 1–15 doi:10.1093/ijnp/pyv124 Advance Access Publication: November 17, 2015 Review review Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis Downloaded from Ying Xu, Maree Hackett, Gregory Carter, Colleen Loo, Verònica Gálvez, Nick Glozier, Paul Glue, Kyle Lapidus, Alexander McGirr, Andrew A. Somogyi, Philip B. Mitchell, Anthony Rodgers http://ijnp.oxfordjournals.org/ The George Institute for Global Health, The University of Sydney, Sydney, Australia (Drs Xu, Hackett, and Rodgers); Centre for Translational Neuroscience and Mental Health, University of Newcastle, Australia (Dr Carter); School of Psychiatry, University of New South Wales & Black Dog Institute, Sydney, Australia (Drs Loo, Gálvez, and Mitchell); Brain and Mind Research Institute, University of Sydney, Australia (Dr Glozier); Department of Psychiatry, University of Otago, New Zealand (Dr Glue); Departments of Psychiatry and Neurobiology, Stony Brook University, Stony Brook, NY (Dr Lapidus); Department of Psychiatry, University of British Colombia, Canada (Dr McGirr); Discipline of Pharmacology, Faculty of Health Sciences, The University of Adelaide, Adelaide, Australia (Dr Somogyi). by Karin Lavoie on April 20, 2016 Correspondence: Colleen Loo, MD, School of Psychiatry, University of New South Wales & Black Dog Institute, Sydney, Australia ([email protected]). Abstract Background: Several recent trials indicate low-dose ketamine produces rapid antidepressant effects. However, uncertainty remains in several areas: dose response, consistency across patient groups, effects on suicidality, and possible biases arising from crossover trials. Methods: A systematic search was conducted for relevant randomized trials in Medline, Embase, and PsycINFO databases up to August 2014.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Analytical Studies on the Kavain Metabolism in Human Specimen and Liver Cell Lines
    Analytical studies on the kavain metabolism in human specimen and liver cell lines Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Vorgelegt von Fuad Ali Tarbah aus Derna, Libyen Düsseldorf 2003 Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Referent: Prof. Dr. Th. Daldrup Korreferent: Prof. Dr. G. Willuhn, Prof. Dr. H. Weber Tag der mündlichen Prüfung: 17. 12. 2003 Parts of this Ph.D. Thesis have already been presented and/or published in: Tarbah F. A., Mahler H., Temme O. and Daldrup Th. Mass spectral characterisation of hepatic cell metabolites of D,L-kavain using HPLC and GC/MS systems. Special issue: 37th TIAFT triennial meeting “Problems of Forensic Sciences” XLII: 173-180 (1999) Tarbah F. A., Mahler H., Temme O. and Daldrup Th. Determination of D,L-kavain and its metabolites in blood, serum and urine. Rapid quantitative method using fluid/fluid extraction and gas chromatography/mass spectrometry (GC/MS). Poster in 79. Jahrestagung der Deutschen Gesellschaft für Rechtsmedizin, Medizinische Einrichtungen der Universität / Gesamthochschule Essen (2000) Tarbah F., Mahler H., Kardel B., Weinmann W., Hafner D. and Daldrup Th. Kinetics of kavain and its metabolites after oral application. J. Chromatogr. B 789 (1): 115-130 (2003) Cabalion P., Barguil Y., Duhet D., Mandeau A., Warter S., Russmann S., Tarbah F. and Daldrup Th. Kava in modern therapeutic uses: to a better evaluation
    [Show full text]
  • Piper Methysticum) in Rats
    Graduate Theses, Dissertations, and Problem Reports 2008 Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats Natalie R. Bruner West Virginia University Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Bruner, Natalie R., "Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats" (2008). Graduate Theses, Dissertations, and Problem Reports. 4358. https://researchrepository.wvu.edu/etd/4358 This Thesis is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Thesis in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Thesis has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats Natalie R. Bruner Thesis submitted to the Eberly College of Arts and Sciences at West Virginia University in Partial Fulfillment of the Requirements for the Degree of Master of Science in Psychology Karen G. Anderson, Ph. D., Chair Kennon A. Lattal, Ph.D. Hawley Montgomery-Downs, Ph.D. Department of Psychology Morgantown, WV 2008 Keywords: drug discrimination, kava, chlordiazepoxide ABSTRACT Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats Natalie R.
    [Show full text]
  • Piper Methysticum)
    Journal of Student Research (2015) Volume 4, Issue 2: pp. 69-72 Research Article A Closer Look at the Risks vs. Benefits of Kava (Piper methysticum) Anan A. Husseina If you took a trip to Fiji, the locals would probably welcome you with a drink of Kava. For centuries, the indigenous people of the South Pacific Islands have used the roots of a plant known as Kava. Beyond the use of Kava as a psychoactive substance, it has been incorporated as a cultural drink that is used in many ceremonies. In the late 1990’s Kava use spread quickly in Western countries including Europe, North America, and Australia. It was used as a treatment for anxiety. But just as quickly as it spread, the enthusiasm for it faded, because it was banned or restricted in many Western countries following reports of liver toxicity. In the United States, the Food and Drug Administration’s (FDA) concern for safety prompted a request for more research on the substance. The issues of safety and efficacy remain more specifically whether the benefits of using Kava outweigh the risks. History Kava is a beverage made from the roots of the plant included alcohol, cocaine, tobacco, and heroin. The findings Piper methysticum, and has been used historically in the suggest that kava may reduce the craving associated with the South Pacific Islands as a ceremonial drink. Kava was aforementioned substances, which may make kava a great introduced in Europe around the 1700s by Captain James future candidate to help with addiction. 13 Cook and has since spread widely to Australia, Europe, and Although the mechanism of action is not clear, it is the United States.
    [Show full text]
  • (6)-Kavain on Voltage-Activated Inward Currents of Dorsal Root Ganglion Cells from Neonatal Rats
    European Neuropsychopharmacology 9 (1999) 171±176 Short communication Effects of (6)-kavain on voltage-activated inward currents of dorsal root ganglion cells from neonatal rats K. Schirrmachera,* , D. BusselbergÈ 1,a , J.M. Langosch b , J. Walden b , U. Winter c , D. Bingmann a aInstitut f urÈÈ Physiologie, Universitat-GH Essen, Hufelandstrasse 55, 45122 Essen, Germany bPsychiatrische UniversitatsklinikÈ , 79104 Freiburg, Germany cKrewel Meuselbach GmbH, 53783 Eitorf, Germany Received 21 November 1997; accepted 20 January 1998 Abstract Kava pyrones extracted from pepper Piper methysticum are pharmacologically active compounds. Since kava pyrones exhibit anticonvulsive, analgesic and centrally muscle relaxing properties, the in¯uence of a synthetic kava pyrone, (6)-kavain, on voltage- dependent ion channel currents was studied. Effects of (6)-kavain on voltage-activated inward currents were analysed in cultured dorsal root ganglion cells derived from neonatal rats. Voltage-activated Ca211 and Na currents were elicited in the whole-cell con®guration of the patch clamp technique. Extracellularly applied (6)-kavain dissolved in hydrous salt solutions reduced voltage-activated Ca21 and Na1 channel currents within 3±5 min. As the solubility of (6)-kavain in hydrous solutions is low, dimethyl sulfoxide (DMSO) was added to the saline as a solvent for the drug in most experiments. When (6)-kavain was dissolved in DMSO, the drug induced a fast and pronounced reduction of both Ca211 and Na currents, which partly recovered within 2±5 min even in the presence of the drug. The present study indicates that (6)-kavain reduces currents through voltage-activated Na1 and Ca21 channels. 1999 Elsevier Science B.V./ECNP.
    [Show full text]
  • Versatile Asymmetric Synthesis of the Kavalactones
    ORGANIC LETTERS 2004 Versatile Asymmetric Synthesis of the Vol. 6, No. 14 Kavalactones: First Synthesis of 2317-2320 (+)-Kavain Thomas E. Smith,* Mabel Djang, Alan J. Velander, C. Wade Downey,† Kathleen A. Carroll, and Sophie van Alphen Department of Chemistry, Williams College, Williamstown, Massachusetts 01267 [email protected] Received April 1, 2004 ABSTRACT Three asymmetric pathways to the kavalactones have been developed. The first method is chiral auxiliary-based and utilizes aldol reactions of N-acetyl thiazolidinethiones followed by a malonate displacement/decarboxylation reaction. The second approach uses the asymmetric catalytic Mukaiyama additions of dienolate nucleophile equivalents developed by Carreira and Sato. Finally, tin-substituted intermediates, prepared by either of these routes, can serve as advanced general precursors of kavalactone derivatives via Pd(0)-catalyzed Stille couplings with aryl halides. The Kava plant (Piper methysticum) has a long and colorful ported.1 The psychoactive principals are a family of 15 history spanning several thousand years.1 Kava has been used R-pyrone derivatives known as the kavalactones that com- by Pacific Island societies to prepare an intoxicating cer- prise roughly 15% of the dried rootstock. The more prevalent emonial beverage renowned for its relaxing effects and ability of these include kavain (1, Figure 1), dihydrokavain (2), and to promote sociability. Modern use of Kava root, commonly methysticin (3). Structurally, the kavalactones differ chiefly available in dietary supplements labeled “Kava Kava”, is also with respect to their arene substitution patterns and the for its purported anxiolytic2 and soporific qualities. Anal- presence or absence of double bonds along their carbon gesic,3 anesthetic, antifungal, antithrombotic,4 anticonvul- backbones.
    [Show full text]